Status:
UNKNOWN
Off-Label Use of Ribavirin in Management of Mucocutaneous Extrahepatic Manifestations of HCV Infection
Lead Sponsor:
Tanta University
Conditions:
Hepatitis C
Lichen Planus
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
This study will be conducted on 30 patients with mucocutaneous complaints and documented HCV infection. The study will be done at Tropical medicine department , Tanta university. It will be conducted ...
Detailed Description
Hepatitis C virus is a common cause of chronic liver disease worldwide and represent public health problem. The Egyptian Demographic Health Survey (EDHS), a cross sectional survey including hepatitis ...
Eligibility Criteria
Inclusion
- Patients with evidence of HCV infection and mucocutaneous complaint and contraindicated to have standard antiviral therapy.
Exclusion
- Hypersensitivity to Ribavirin
- Pregnant \& Lactating women
- Male partners of pregnant women
Key Trial Info
Start Date :
June 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2014
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT02261662
Start Date
June 1 2014
End Date
November 1 2014
Last Update
October 10 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tanta University Hospital
Tanta, Gharbia Governorate, Egypt, 31111